Royal College of Surgeons in Ireland
Treatment is on target in Crohn’s disease with biologic agents.pdf (219.95 kB)

Treatment is on target in Crohn’s disease with biologic agents

Download (219.95 kB)
journal contribution
posted on 2023-08-11, 11:24 authored by Maria Mikail

Crohn’s disease is a disorder of unknown aetiology, which classically presents with transmural inflammation throughout the gastrointestinal tract, from the mouth to the perianal area. Patients with Crohn’s disease suffer from various non-specific symptoms such as prolonged diarrhoea, abdominal pain, fever and weight loss. To date, treatment has largely involved immunosuppression, but the recent development of a novel class of drugs, the biologics, may revolutionise the treatment of Crohn’s disease. Biologic treatments used in Crohn’s disease include tumour necrosis factor alpha inhibitors (anti-TNFα), adhesion molecule inhibitors, and interleukin-12 (IL-12) and interleukin-23 (IL-23) inhibitors. These biologics target the underlying immunopathogenesis seen in Crohn’s disease, primarily by decreasing pro-inflammatory cytokines. This article reviews the literature to date on infliximab, an anti-TNFα used in moderate to severe Crohn’s disease, and ustekinumab, an IL-12 and IL-23 inhibitor, with a specific focus on mechanisms of action, adverse events, and guidelines for these treatments. 



The original article is available at Part of the RCSIsmj collection:

Published Citation

Mikail M. Treatment is on target in Crohn’s disease with biologic agents. RCSIsmj. 2018;11(1):52-58

Publication Date



  • Undergraduate Research


RCSI University of Medicine and Health Sciences


  • Published Version (Version of Record)